HCA Healthcare (NYSE:HCA) Releases Quarterly Earnings Results, Beats Estimates By $0.19 EPS

HCA Healthcare (NYSE:HCA) released its quarterly earnings results on Friday. The company reported $6.22 earnings per share for the quarter, topping analysts’ consensus estimates of $6.03 by $0.19, RTT News reports. HCA Healthcare had a return on equity of 520.98% and a net margin of 8.52%. During the same quarter in the prior year, the company posted $5.90 earnings per share. HCA Healthcare updated its FY 2025 guidance to 24.050-25.850 EPS.

HCA Healthcare Stock Down 1.1 %

Shares of NYSE HCA opened at $321.77 on Friday. The firm’s 50-day moving average is $314.50 and its two-hundred day moving average is $352.84. The company has a market capitalization of $81.50 billion, a PE ratio of 14.45, a price-to-earnings-growth ratio of 1.09 and a beta of 1.64. The company has a debt-to-equity ratio of 48.71, a current ratio of 1.12 and a quick ratio of 1.00. HCA Healthcare has a 12-month low of $279.93 and a 12-month high of $417.14.

Insider Transactions at HCA Healthcare

In related news, insider Erol R. Akdamar sold 2,900 shares of the company’s stock in a transaction on Thursday, November 14th. The stock was sold at an average price of $353.00, for a total value of $1,023,700.00. Following the completion of the transaction, the insider now directly owns 6,843 shares in the company, valued at approximately $2,415,579. This represents a 29.76 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, SVP Phillip G. Billington sold 3,897 shares of the stock in a transaction on Thursday, November 14th. The stock was sold at an average price of $350.00, for a total value of $1,363,950.00. Following the transaction, the senior vice president now owns 52,702 shares of the company’s stock, valued at $18,445,700. This represents a 6.89 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 1.60% of the company’s stock.

Analyst Ratings Changes

Several brokerages have recently commented on HCA. KeyCorp lowered their target price on shares of HCA Healthcare from $420.00 to $370.00 and set an “overweight” rating on the stock in a report on Tuesday, January 7th. Wells Fargo & Company downgraded HCA Healthcare from an “equal weight” rating to an “underweight” rating and dropped their price target for the stock from $400.00 to $320.00 in a research note on Monday, November 25th. Oppenheimer lifted their target price on HCA Healthcare from $390.00 to $400.00 and gave the company an “outperform” rating in a research report on Monday, October 28th. JPMorgan Chase & Co. reiterated a “neutral” rating and set a $380.00 price target on shares of HCA Healthcare in a report on Tuesday, December 17th. Finally, StockNews.com cut HCA Healthcare from a “strong-buy” rating to a “buy” rating in a research report on Monday, November 4th. One analyst has rated the stock with a sell rating, three have given a hold rating, twelve have assigned a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $385.27.

HCA Healthcare Company Profile

HCA Healthcare, Inc, through its subsidiaries, owns and operates hospitals and related healthcare entities in the United States. It operates general and acute care hospitals that offers medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy.